IMMUNOVANT, INC.

IMVT
Delayed Nasdaq - 04:00 2022-12-02 pm EST
14.68 USD +5.84%

Turn to zoom
Prev.14.68000000
Open13.90000000
High14.71000000
Low13.67000000
Volume815 039
Latest news
11/16
11/08
11/07
11/07
Chart IMMUNOVANT, INC.
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishBullish
Resistance15,123,816,2
Spread/Res.-2,9%-38%-9,2%
Spread/Supp.26%130%136%
Support11,76,376,21
Financials
Sales 2023 - - -
Net income 2023 -198 M - -
Net cash 2023 667 M - -
P/E ratio 2023 -9,18x
Yield 2023 -
Capitalization 1 896 M 1 896 M -
EV / Sales 2023 -
EV / Sales 2024 -
Nbr of Employees 124
Free-Float 41,3%
Company
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. The Company's product candidate, batoclimab, is a fully human, monoclonal antibody targeting the neonatal fragment crystallizable receptor....
Sector :
Other Biotechnology & Medical Research
Calendar :
2023-02-16 Earnings Release
Trading Rating :
Investor Rating : -

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 14,68 $
Average target price 13,00 $
Spread / Average Target -11,4%